Regenxbio

RGNX

Market cap $714M

14.11 USD

+0.28

2.02%

At close Updated Dec 16, 4:00 PM EST

Pre-market

After hours

14.11

0.00

1 day

2.02%

5 days

11.54%

1 month

26.66%

3 months

52.38%

6 months

54.04%

Year to date

79.52%

1 year

65.22%

5 years

-67.47%

10 years

-25.38%

About: Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Employees: 353

Healthcare Biotechnology